Company Presentation

FoRx Therapeutics develops innovative cancer-specific therapeutics targeting key proteins in distinct DNA Damage Response (DDR) pathways that cancer cells depend on for their survival. The company’s pipeline encompasses novel, first-in-class as well as differentiated, best-in-class programs. Our lead program is a highly potent and selective PARG inhibitor with strong evidence for best-in-class potential (Development Candidate stage).